Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Sarepta Therapeutics Inc (SRPT) reports a robust 39% revenue growth, achieving profitability while navigating strategic ...

Sarepta Therapeutics (NASDAQ: SRPT) Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET ...

Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

Analyst Gil Blum of Needham maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated ...

Find Therapeutics, TeraImmun, AptaTargets, Trethera, Aditxt, SetPoint Medical, Sarepta Therapeutics, Nucleome Therapeutics, Vaccinex Inc., and others are evaluating new multiple sclerosis drugs to ...